Ovarian Hyperstimulation Syndrome Treatment & Management

  • Author: Joanna Horwitz, MD; Chief Editor: Richard Scott Lucidi, MD   more...
 
Updated: Mar 23, 2012
 

Treatment Based on Degree of Hyperstimulation

Mild hyperstimulation

Treatment for ovarian hyperstimulation syndrome (OHSS) is supportive, as needed. Mild ovarian hyperstimulation can develop into moderate or severe disease, especially if conception ensues. Therefore, women with mild disease should be observed for enlarging abdominal girth, acute weight gain, and abdominal discomfort on an ambulatory basis for at least 2 weeks or until menstrual bleeding occurs.

Moderate hyperstimulation

Treatment of moderate OHSS consists of observation, bed rest, provision of adequate fluids, and sonographic monitoring of the size of cysts. Serum electrolyte concentrations, hematocrits, and creatinine levels should also be evaluated.

Some physicians have their outpatients keep track of their fluid intake and output. Intake or output less than 1000 mL/d or a discrepancy in fluid balance greater than 1000 mL/d is a cause for concern.[18]

The beginning of the resolution of OHSS is apparent when the cysts shrink, as seen on 2 consecutive ultrasonographic examinations, and when clinical symptoms recede. In contrast, early detection of progression to the severe form of the syndrome is marked by continuous weight gain (≥ 2 lb/d), increased severity of existing symptoms, or appearance of new symptoms (eg, vomiting, diarrhea, or dyspnea).[16]

Severe hyperstimulation

Experience with severe OHSS is mandatory for appropriate treatment. One should transfer the patient to a different center if no one who is experienced in managing severe OHSS is available at the present location.

Severe OHSS is not common, but it is dangerous. Severe and critical forms of OHSS are potentially lethal disorders, and history taking and physical examination are paramount at the time of admission. In most clinical situations, patients require bed rest. Daily physical examination should consist of measuring the patient's weight and abdominal girth. Fluid balance must be assessed every 4 hours.

Medical treatment of severe hyperstimulation is directed at maintaining intravascular blood volume. Simultaneous goals are correcting the disturbed fluid and electrolyte balance, relieving secondary complications of ascites and hydrothorax, and preventing thromboembolic phenomena.

The main interventions are fluid management and correction of hypovolemia. These measures consists of initial fast intravenous administration of normal saline. Dextrose 5% in normal saline or normal saline is infused at a rate of 125-150 mL/h with 4-hour tabulations of urine production. If urine production is restored or improved, a maintenance protocol is started. The patient should be closely monitored for clinical signs of overhydration. If urine output is unsatisfactory, hyperosmolar intravenous therapy is indicated with an infusion of 200 mL of 25% human albumin. The use of diuretics in patients with low urine production and hypovolemia is counterproductive and dangerous.[16]

Close surveillance of fluid management is necessary. Intravenous fluid administration is stopped when urine production, appetite, or interest in drinking increases and when an overall clinical improvement is observed. In the resolution phase of severe OHSS, the patient's fluid intake should be restricted to avoid renewed hemodilution.

To prevent thrombosis, subcutaneous heparin 5000-7500 U/d is begun on the first day of admission. It is stopped after adequate mobilization is achieved.

To manage ascites, ultrasonographic-guided abdominal or vaginal paracentesis is indicated if the patient has severe discomfort or pain or if she has pulmonary or renal compromise.[21] The vaginal procedure entails the same setup as that used for transvaginal follicular puncture. Whelan and Vlahos advise that an anesthesiologist be present. Paracentesis may be repeated if required.[18]

Critical hyperstimulation

Critical OHSS may include renal failure, hepatic damage, thromboembolic phenomena, ARDS, and multiorgan failure.[22] Its management and treatment requires intensive care in a critical care unit.

Intensive care should include invasive monitoring of circulatory indicators, including venous pressure and wedge pressure. The patient may need extra oxygenation (assisted ventilation).

If renal failure is present, an intravenous dopamine regimen should be started. To treat thromboembolism, therapeutic doses of anticoagulants should be administered. Thoracocentesis should be performed in the case of severe hydrothorax. Finally, if a pregnancy is maintaining a life-threatening OHSS, therapeutic abortion must be considered.

Next

Clinical Pearls

What not to do

  • Aggressive palpation of the abdomen: This can precipitate follicular rupture.
  • Early surgical intervention: Early surgery may cause extensive bleeding from ovarian cysts. However, surgery is mandated if torsion or rupture has occurred.
  • Neglect of deterioration in organs and systems: Remember that OHSS is a syndrome of multiorgan dysfunction.

What to do

  • Maintain a high degree of clinical suspicion and a low threshold for admission.
  • Implement early surgical intervention in cases of ovarian torsion or hemorrhage.
  • Perform paracentesis to address ascites. This decreases pressure on inferior vena cava and diaphragm.
  • Place a transthoracic tube to manage pleural effusions.
Previous
Next

Resolution

After several days, third-space fluid begins to re-enter the intravascular space, hemoconcentration reverses, and natural diuresis ensues. Intravenous fluids may be tapered as the patient's oral intake increases. Complete resolution typically takes 10-14 days from the onset of initial symptoms.

Careful maintenance of blood volume, correction of electrolyte imbalances, and relief of secondary complications of ascites and hydrothorax are generally sufficient to support the patient during the severe phase of ovarian hyperstimulation. Anticoagulant therapy is usually unnecessary if these therapies are promptly administered. Blood coagulation may be monitored because of the danger of disseminated intravascular clotting.

Previous
Next

Surgical Care

Ovarian hyperstimulation syndrome is a self-limiting disease. Therefore, treatment should be conservative and directed at symptoms. Medical therapy suffices for most patients. Women with severe symptoms often require intensive medical care. Surgery is necessary only in extreme cases, such as in the case of a ruptured cyst, ovarian torsion, or internal hemorrhage.

Surgical management further aggravates electrolyte imbalances and increases morbidity. Ascites can be tapped by means of paracentesis. Harvesting of eggs in women with OHSS can lead to hemorrhage and peritonitis. However, tapping follicles when they are of moderate size may prevent OHSS. Laparotomy during torsion and intraperitoneal hemorrhage is life saving and recommended.

Previous
Next

Consultations

In severe cases of OHSS, consultation with a physician specializing in fluid and electrolyte imbalances is warranted. For some cases, aggressive treatment in the surgical intensive care unit may be required.

Previous
Next

Diet

Ensure that patient receives plenty of hydration.

Previous
Next

Activity

Activity should be minimal. Physical examination should be performed gently because of the tendency of follicles to rupture.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Joanna Horwitz, MD  Staff Physician, Department of Obstetrics and Gynecology, Loyola University Medical Center

Joanna Horwitz, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists and American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Ramesh S Pundi, MD  Attending Physician, Department of Obstetrics and Gynecology, Genesis Health System, Davenport, Iowa

Ramesh S Pundi, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists and Indian Medical Association

Disclosure: Nothing to disclose.

Josef Blankstein, MD  Chairman, Department of Obstetrics and Gynecology, Rosalind Franklin University of Health Sciences, Chicago Medical School

Josef Blankstein, MD is a member of the following medical societies: Academy of Medicine Cleveland/Northern Ohio Medical Assn, American College of Obstetricians and Gynecologists, and Ohio State Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Suzanne R Trupin, MD, FACOG  Clinical Professor, Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Urbana-Champaign; CEO and Owner, Women's Health Practice; CEO and Owner, Hada Cosmetic Medicine and Midwest Surgical Center

Suzanne R Trupin, MD, FACOG is a member of the following medical societies: American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, Association of Reproductive Health Professionals, International Society for Clinical Densitometry, and North American Menopause Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Michel E Rivlin, MD  Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, and Royal College of Surgeons of Edinburgh

Disclosure: Nothing to disclose.

Frederick B Gaupp, MD  Consulting Staff, Department of Family Practice, Hancock Medical Center

Frederick B Gaupp, MD is a member of the following medical societies: American Academy of Family Physicians

Disclosure: Nothing to disclose.

Chief Editor

Richard Scott Lucidi, MD  Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists and American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Additional Contributors

For their industrious work in collecting articles and research, Estello Escudero, MA LibSc, Mt Sinai Hospital Library, and Merly Arceo, BA LibSc, Mt Sinai Hospital; and, for his unstinting support and encouragement, Dr Jos Blankstein.

References
  1. Myrianthefs P, Ladakis C, Lappas V, et al. Ovarian hyperstimulation syndrome (OHSS): diagnosis and management. Intensive Care Med. May 2000;26(5):631-4. [Medline].

  2. Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. Jun 1989;44(6):430-40. [Medline].

  3. Morris RS, Paulson RJ. Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril. Dec 1994;62(6):1105-14. [Medline].

  4. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod. Jun 1997;12(6):1129-37. [Medline].

  5. Zalel Y, Katz Z, Caspi B, et al. Spontaneous ovarian hyperstimulation syndrome concomitant with spontaneous pregnancy in a woman with polycystic ovary disease. Am J Obstet Gynecol. Jul 1992;167(1):122-4. [Medline].

  6. Beerendonk CC, van Dop PA, Braat DD, et al. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv. Jul 1998;53(7):439-49. [Medline].

  7. Brinsden PR, Wada I, Tan SL, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol. Oct 1995;102(10):767-72. [Medline].

  8. Insler V, Lunenfeld B. Pathogenesis of ovarian hyperstimulation syndrome. In: Gomel V, Leung PCK. In Vitro Fertilization and Assisted Reproduction. Bologna, Italy: Monduzzi Editore; 1997:433-9.

  9. Abramov Y, Elchalal U, Schenker JG. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. Apr 1999;71(4):645-51. [Medline].

  10. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril. May-Jun 1969;20(3):443-50. [Medline].

  11. Martin RA, Edraki B, Norris RL. Ovarian hyperstimulation syndrome in the emergency department: a case report. J Emerg Med. Jul-Aug 1994;12(4):481-4. [Medline].

  12. Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod. May 1994;9(5):792-9. [Medline].

  13. Rutkowski A, Dubinsky I. Ovarian hyperstimulation syndrome: imperatives for the emergency physician. J Emerg Med. Jul-Aug 1999;17(4):669-72. [Medline].

  14. Delvigne A, Demoulin A, Smitz J, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. Sep 1993;8(9):1353-60. [Medline].

  15. Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod. Oct 1997;12(10):2167-73. [Medline].

  16. Speroff L, Fritz M. Clinical Gynecological Endocrinolgy and Infertility. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:1999-1200.

  17. Levin ER, Rosen GF, Cassidenti DL, et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. J Clin Invest. Dec 1 1998;102(11):1978-85. [Medline].

  18. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. May 2000;73(5):883-96. [Medline].

  19. Wang TH, Horng SG, Chang CL, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. Jul 2002;87(7):3300-8. [Medline].

  20. Blankstein J, Lunenfeld S, Mashiach S. Introduction of Ovulation and In Vitro Fertilization. Chicago, Ill: YearBook Medical; 1986.

  21. Levin I, Almog B, Avni A, et al. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril. May 2002;77(5):986-8. [Medline].

  22. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. Aug 1992;58(2):249-61. [Medline].

  23. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. Feb 15 2012;2:CD008605. [Medline].

  24. Herman A, Raziel A, Strassburger D, et al. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone. Hum Reprod. Jul 1996;11(7):1552-7. [Medline].

  25. Lunenfeld B, Insler V, Glezerman M. Diagnosis and Treatment of Functional Infertility. 3rd ed. Berlin, Germany: Blackwell Wissenschaft; 1993:98.

Previous
Next
 
Ultrasonographic presentation of ovarian hyperstimulation syndrome.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.